Dalriada Drug Discovery

Profile

Dalriada is a leading North American partnered discovery company that is pioneering its novel Turn-Key™ model in small molecule drug discovery. Purpose-built and partner-centric, the organization integrates world-class expertise across synthetic, medicinal, and computational chemistry; structural and in vitro biology; chemoproteomics; and discovery strategy—enabling and accelerating even the most challenging programs from inception. As part of its commitment to innovation, Dalriada also offers iCLASS, a revolutionary TechBio platform that merges multi-proteomics-centered data generation with next-generation machine learning. iCLASS establishes a new vertical in drug discovery, unlocking biologically relevant and highly translatable insights to maximize R&D efficiency—promising zero-dollar loss per R&D dollar invested. With a robust portfolio of early-stage assets, including programs targeting previously "undruggable" mechanisms, iCLASS is reshaping what’s possible in drug discovery.

Product/Service Information:

The typical end users of Dalriada’s services include pharmaceutical and biotechnology companies, as well as emerging scientific ventures engaged in or reliant on early-stage small-molecule drug discovery research. Its partners span a range of therapeutic areas and modalities and leverage Dalriada’s expertise to accelerate hit identification, target validation, and lead optimization efforts.

Dalriada Drug Discovery logo

Website

dalriadatx.com

Contact


Event details

Date: October 8 - 10, 2025

Event contact

Stephen Ip
Senior International Market Consultant
Japan and Korea

Participants

6 in total